Fresenius Medical Care AG & Co. KGaA Q3 FY2025 earnings call

Management Statement and Operational Highlights

• FME Reignite Strategy: Made meaningful progress in Q3 with 10% organic revenue growth, operating income growth 28%, and operating margin expanding to 11.7%. Launched a EUR 1 billion share buyback program, with 4.35 million shares repurchased for EUR 188 million by Oct 31.
• U.S. Market Challenges: Navigating government shutdown impacts on health care policy decisions, requiring flexible planning and agile business operations.
• FME25+ Program: Generated EUR 47 million in sustainable savings in Q3, with total savings for 2025 reaching EUR 174 million.
• High-Volume HDF Rollout: Launched the 5008X machine in the U.S., with interest at the ASN Kidney Week. Early rollout of select clinics provided insights for the 2026 large-scale launch.
• Quality and Safety Initiatives: Progressed in treatment adherence, with controllable missed treatments decreasing; antimicrobial catheter treatments increased to 84% of eligible patients; flu vaccination rates in U.S. clinics at 72% and expected to reach 85% by year-end.

Segment Performance

• Care Delivery: Realized organic revenue growth of 6%. In the U.S., organic growth of 6% was driven by favorable rate and payer mix development, positive contributions from phosphate binders, and reduced implicit price concessions. Internationally, organic growth was 4% including 1.2% same market treatment growth. Margin was 14.5%, at the upper end of 2025 target margin band.
• Value-Based Care: Realized 42% organic revenue growth due to higher member months from contracting growth and a growing provider network. However, operating income was a loss of EUR 21 million. Delays in CMS reporting data for the CKCC program added to earnings fluctuations.
• Care Enablement: Achieved strong revenue and organic growth of 5%. Operating income increased 38%, leading to a margin increase of 200 basis points to 7.6% due to volume growth, positive pricing momentum, and sustainable savings from the FME25+ program.

Guidance

• Full year 2025 outlook reaffirmed, on track to achieve guidance. Value-Based Care segment expected at the top end of the low single-digit percent revenue growth range. Operating income growth expected to accelerate, with FME25+ delivering around EUR 40 million more for 2025 (total EUR 220 million), and pharma contributions from phosphate binders exceeding expectations by EUR 80 million.
• 2026 planning ongoing, considering factors like mix of phosphate binders, price erosion, ACA tax subsidies, CMS pricing, and tariffs. Q4 volume data will shape 2026 outlook.

Risks

• Government shutdown in the U.S. impacting health care policy decisions.
• Delays in CMS reporting data for the CKCC program affecting Value-Based Care earnings.
• Transactional exchange rate impact affecting Care Enablement margin.
• Elevated mortality levels impacting treatment volume and related metrics.

Question and Answer

Q: On margin guidance and treatment adherence.

A: Helen Giza mentioned continuous improvement in all segments, progress in missed treatments, referrals, and catheter rates, noting mortality levels are still elevated but efforts to control missed treatments and improve patient care are underway.

Q: On phosphate binders benefit and Medicare Advantage.

A: Helen Giza stated phosphate binder benefit exceeded expectations, with the full year benefit estimated at EUR 180 million. Medicare Advantage mix was steady with no major impact seen.

Q: On EBIT guidance risks and phosphate binder Q3 benefit.

A: Helen Giza and Martin Fischer discussed the EBIT range, with momentum from FME25+ and phosphate binders offsetting some negatives, and Martin Fischer provided that Q3 phosphate binder benefit was a mid-double-digit million amount.

Q: On FME25+ reasons and HDF rollout.

A: Martin Fischer highlighted FME25+ momentum driving progress, and Helen Giza discussed the HDF rollout progress, with early clinics providing insights for 2026 launch.

Q: On Care Delivery moving parts and HDF benefit.

A: Helen Giza emphasized volume growth importance for Care Delivery, and discussed HDF benefit phasing, expecting improvements as patients ramp up on the treatment.

Q: On competitor impact and volumes.

A: Helen Giza noted 2026 planning is ongoing, considering various factors, and volume mix is being monitored closely.

Q: On HVHDF rollout impact and Care Delivery components.

A: Helen Giza talked about HDF referral impact, and Martin Fischer discussed implicit price concessions and rate mix assumptions as positive contributors to Care Delivery.